Takeda Pharmaceutical Company Limited has announced the availability of Fomepizole Intravenous Infusion 1.5g Takeda, or fomepizol, for the treatment of ethylene glycol and methanol poisonings in Japan. Fomepizole, an alcohol dehydrogenase inhibitor, is marketed and distributed by Paladin Labs Inc. in Canada and is the standard treatment for ethylene glycol and methanol poisonings.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4,309 JPY | +1.63% |
|
+1.70% | +6.29% |
04:47pm | Asian Equities Traded in the US as American Depositary Receipts Tumble in Wednesday Trading | MT |
09:59am | Zydus Lifesciences Signs Licensing Pact to Market Vonoprazan in India | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.29% | 42.37B | |
+55.35% | 848B | |
+31.64% | 627B | |
-0.10% | 363B | |
+15.47% | 318B | |
+13.10% | 299B | |
+15.51% | 243B | |
+16.72% | 225B | |
+16.54% | 179B | |
+4.31% | 167B |
- Stock Market
- Equities
- 4502 Stock
- News Takeda Pharmaceutical Company Limited
- Takeda Pharmaceutical Company Limited Launches Treatment for Ethylene Glycol and Methanol Poisonings in Japan